Search
Prostate
A032304 (MBMC Only)
Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL)
CCTG PR26 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
EAY191-N5 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors. A ComboMATCH Treatment Trial
SWOG S2312
A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
NRG-GU013
The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
EAY191 (ComboMATCH) **Temporarily Suspended** **If biopsy needed, TBD at MBMC**
Molecular Analysis for Combination Therapy Choice
ALLIANCE A212102 ***Upcoming Closure to Accrual 12/11/26*** ***Participant Engagement Portal (PEP) is Closed to New Patient Registration as of 9/15/25*** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**
Blinded Reference Set For Multicancer Early Detection Blood Tests
A031702 **effective 10/15/26, at 4pm ET, registration to Cohort J: – Non-Prostate Bone Only Metastatic GU Tumors will be suspended *** (Cohort B (adenocarcinoma of the bladder), E (penile cancer), F (sarcomatoid renal cell carcinoma), G (miscellaneous GU tract histologic variants), I (renal medullary carcinoma) and Cohort K (Renal Collecting Duct Carcinoma) are Temporarily Closed to Accrual)
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
S1802 **9/9/26 – Effective immediately stop collecting/submitting whole blood specimens to Dr. Amir Goldkorn’s laboratory as outlined in protocol section 15.3***
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
